Browsing by Author Schadendorf, D

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)Citation
2017Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialLong, Georgina; Arance, A; Ascierto, Paolo A; Del Vecchio, M; Di Giacomo, A; Dummer, R; Dutriaux, Caroline; et al, Various; Gutzmer, R.; Rutkowski, Piotr; Schadendorf, D; Northern Clinical School: MedicineBinimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, 4, 2017,pp 435-445
2016Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trialsKefford, Richard (Rick); Long, Georgina; Carver, Jennifer; Casey, Michelle; Flaherty, Keith; Gagnon, Robert; Goodman, Vicki; Haney, Patricia; Hauschild, Axel; Hwu, Patrick; Legos, Jeffrey J.; Martin, Anne-Marie; Mazumdar, Jolly; O'Hagan, Anne; Santiago-Walker, Ademi; Schadendorf, D; Western Clinical School: Westmead Institute for Medical Res; Central Clinical School: The Sydney Cancer CentreCorrelation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials, Clinical Cancer Research, vol.22, 3, 2016,pp 567-574
2016Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsLong, Georgina; Davies, Michael; Flaherty, Keith; Grob, Jean-Jacques; Lane, Stephen; Legenne, Philippe; Mak, Carmen; Nathan, Paul; Ribas, Antoni; Robert, Caroline; Schadendorf, D; Northern Clinical School: MedicineFactors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials, The Lancet Oncology, vol.17, 12, 2016,pp 1743-1754
2013Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic MelanomaKefford, Richard (Rick); Long, Georgina; Amaravadi, Ravi; Arya, Niki; Ascierto, Paolo; et al, Various; Grob, Jean-Jacques; Guckert, Mary; Hamid, Omid; Kim, Kevin; Lebbe, Celeste; Minor, David; O'Hagan, Anne; Ribas, Antoni; Schadendorf, D; Simeone, Ester; Wilhelm, Tabea; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentrePhase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma, Journal of Clinical Oncology, vol.31, 26, 2013,pp 3205-3211
2016The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor geneScolyer, Richard; Wilmott, James; Edqvist, Per Henrik; Elchebly, Mounib; et al, Various; Klein, Kathleen Oros; Papadakis, Andreas; Pontén, Fredrik; Redpath, Margaret; Schadendorf, D; Van Kempen, Léon; Van Rijk, Anke; Central Clinical School: Pathology; Central Clinical School: SurgeryThe protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene, Science Translational Medicine, vol.8, 369, 2016,pp 1-13
2014Surrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trialsKefford, Richard (Rick); Long, Georgina; Ascierto, Paolo; Dummer, R; Eggermont, Alexander; Flaherty, Keith; Hauschild, A; Hennig, Michael; Kirkwood, John; Lee, Sandra J; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant A.; O'Day, Steven; Patel, Poulam; Robert, Caroline; Schadendorf, D; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreSurrogate endpoints for overall survival in metastatic melanoma: A meta-analysis of randomised controlled trials, The Lancet Oncology, vol.15, 3, 2014,pp 297-304
2017Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsLong, Georgina; Chiarion-Sileni, Vanna; Dutriaux, Caroline; et al, Various; Garbe, Claus; Hauschild, Axel; Karaszewska, Boguslawa; Levchenko, Evgeny; Schachter, Jacob; Schadendorf, D; Stroiakovski, Daniel; Northern Clinical School: MedicineThree-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials, European Journal of Cancer, vol.82, N/A, 2017,pp 45-55
2015Treatment algorithms in stage IV melanomaKefford, Richard (Rick); Dummer, R; Eggermont, Alexander; Espinosa, E; Gogas, Helen; Grob, Jean-Jacques; Hauschild, Axel; Martin-Algarra, Salvador; Robert, C; Rutkowski, Piotr; Schadendorf, D; Western Clinical School: Westmead Institute for Medical ResTreatment algorithms in stage IV melanoma, American Journal of Therapeutics, vol.22, 1, 2015,pp 61-67